Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

153 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y. Paul C, et al. Among authors: guenther l. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):68-72. doi: 10.1111/jdv.14581. Epub 2017 Oct 6. J Eur Acad Dermatol Venereol. 2018. PMID: 28881462 Clinical Trial.
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P. Guenther L, et al. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4. J Eur Acad Dermatol Venereol. 2017. PMID: 28573743 Clinical Trial.
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. van de Kerkhof P, et al. Among authors: guenther l. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27910156 Clinical Trial.
153 results